Neon Therapeutics Treats First Patient in Ph Ib Trial Evaluating Personal Cancer Vaccine NEO-PV-01 Plus Keytruda/Chemo Combination

Neon Therapeutics, announced on 5/8/18 that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), along with chemotherapy. The trial is being conducted in collaboration with Merck, also known as MSD outside of the U.S. and Canada.